Sino Biopharmaceutical’s Stock Price Dips to 3.89 HKD, Recording a 1.52% Decline: A Detailed Analysis of 1177’s Market Performance

Sino Biopharmaceutical (1177)

3.89 HKD -0.06 (-1.52%) Volume: 137.7M

Sino Biopharmaceutical’s stock price currently stands at 3.89 HKD, experiencing a slight dip of -1.52% this trading session, despite its impressive YTD growth of +21.56%. With a robust trading volume of 137.7M, it continues to be a significant player in the pharmaceutical sector.

Latest developments on Sino Biopharmaceutical

Sino Biopharmaceutical‘s stock price saw movements today following key events in the company’s recent history. Two years after a $161M cash exit to Sino’s invoX, F-star management has taken the company private. This comes on the heels of Sino Biopharmaceutical‘s TQB6411 Clinical Trial Application being accepted and receiving approval for a clinical trial of a new cancer drug. These developments have likely impacted investor sentiment and contributed to the fluctuations in Sino Biopharmaceutical‘s stock price today.

Sino Biopharmaceutical on Smartkarma

Analysts on Smartkarma, like Xinyao (Criss) Wang, have provided insights on Sino Biopharmaceutical‘s recent move to acquire Hob Biotech. The analysis suggests that the price paid by Sino Biopharm for the acquisition is considered expensive, with the main goal being to achieve an A-share listing rather than asset appreciation. The future valuation of Hob Biotech is dependent on the assets it will receive from Sino Biopharm, and synergies between the two companies are seen as limited.

The research report indicates that Sino Biopharm’s acquisition of Hob may not bring significant financial value or asset appreciation. The purchase price of RMB33.74/share is deemed costly given the small market size and weak fundamentals. Analysts like Xinyao (Criss) Wang lean towards a bullish sentiment on Hob Biotech, suggesting it may be a good time to buy Hob and sell Sino Biopharmaceutical based on the potential for A-share listing and future valuation performance.

A look at Sino Biopharmaceutical Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, Sino Biopharmaceutical Limited has a promising long-term outlook. With solid scores in resilience and momentum, the company shows potential for steady growth and stability in the biopharmaceutical industry. While its value and dividend scores are average, its growth prospects are also rated as moderate.

Sino Biopharmaceutical Limited focuses on researching, developing, and selling biopharmaceutical products for various medical treatments. Specializing in ophthalmia and hepatitis treatments, the company aims to provide modernized Chinese medicine and chemical medicine to address these health concerns. With a balanced overall outlook, Sino Biopharmaceutical Limited is positioned to make a mark in the competitive pharmaceutical market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma